drugset / Trial / NCT06786338
A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study looks at how well and safely SGB-9768 works for patients with certain kidney diseases: primary IgA nephropathy, C3 glomerulopathy, and immune complex-related membranoproliferative glomerulonephritis. It's a phase 2 trial done at several locations where both patients and doctors know what treatment is being given.
Timeline
- Start
- 2025-04-01
- Primary completion
- 2026-07-01
- Completion
- 2026-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SGB-9768 | Unknown | — | Subcutaneous |